Category Archives: Psoriasis

This article was originally published here

Dermatol Ther (Heidelb). 2022 Feb 1. doi: 10.1007/s13555-022-00684-3. Online ahead of print.

ABSTRACT

INTRODUCTION: Dimethyl fumarate (DMF) is approved as oral systemic treatment for moderate-to-severe psoriasis. Scarce evidence is available for DMF treatment in psoriatic patients at the time of COVID-19 pandemic. The objective of this study was to assess the long-term effectiveness and safety of DMF monotherapy in moderate-to-severe psoriasis during the COVID-19 pandemic period.

METHODS: This multicenter, retrospective study included patients with moderate-to-severe psoriasis who had received a 48-week DMF treatment during the COVID-19 pandemic. Selected outcomes were: variation of mean PASI, proportion of patients achieving PASI50 and PASI75, variation of mean PGA and face PGA, genital PGA, scalp PGA, mean itch VAS and mean DLQI.

RESULTS: Forty-four patients were enrolled, and four patients became COVID-19 positive during the observation period but did not discontinue DMF therapy. DMF produced a significant improvement of signs and symptoms of psoriasis as expressed by mean PASI variation from 13.07 at baseline to 6.11 at week 48 (p < 0.0001), itch VAS from 3.22 at baseline to 1.18 at week 48 (p < 0.001), PGA from 2.84 at baseline to 1.30 at week 48 (p < 0.0001) and DLQI from 13.09 at baseline to 6.07 at week 48 (p < 0.0001). The percentage of patients who achieved PASI50 and PASI75 was 4.55% at week 4 and 59.09% at week 48 and 0% at week 4 and 22.73% at week 48, respectively. A clinical important decrease of mean PGA score was observed in all subgroups, face psoriasis, genital psoriasis and scalp psoriasis. Adverse events were predictable and manageable.

CONCLUSIONS: DMF monotherapy is an effective and safe treatment option in moderate-to-severe psoriasis also in patients who develop SARS-CoV-2 infection.

PMID:35103934 | DOI:10.1007/s13555-022-00684-3

Read more:
Dimethyl Fumarate's Effectiveness and Safety in Psoriasis: A Real-Life Experience During the COVID-19 Pandemic - DocWire News

Latest Plaque Psoriasis Treatment Market report added by In4Research provides major industry dynamics such as growth drivers, current and future trends, latest developments, threats, challenges, and opportunities in the global market are deeply analyzed. The competitive landscape of the Global Plaque Psoriasis Treatment Market, along with the profiles of the major companies is presented in the report. Regional Market analysis covers North America, China, Africa, Germany, APAC, and more regions have been analyzed individually for a more granular view of the performance of each region in the Plaque Psoriasis Treatment Market and the varying reasons for its positive and negative growth.

The Plaque Psoriasis Treatment Market Report Covers Major Players:

To Get Sample Copy of Plaque Psoriasis Treatment Market Report with Complete TOC, Figures & Graphs Connect with us at https://www.in4research.com/sample-request/60819

The report on the Plaque Psoriasis Treatment market provides a brief overview of the market along with the product definition and market scope. The sections following the introductory chapter provide an in-depth study of the market based on extensive research analysis. Along with the market dynamics, the report also presents a comprehensive analysis of the market covering the supply and demand forces.

Plaque Psoriasis Treatment Market Segmentation:

The global market for Plaque Psoriasis Treatment is set to find a segmentation in the report that would be based on type and application. These segments have a better acceptance of various factors that can be taken into consideration to understand how the market can chart the future path.

Plaque Psoriasis Treatment Market Breakdown based on Product Type:

Plaque Psoriasis Treatment Market Breakdown based on Application:

Plaque Psoriasis Treatment Consumption Breakdown Data by Region

For more Customization, Connect with us at https://www.in4research.com/customization/60819

Key Topics Covered in Plaque Psoriasis Treatment Research Study are:

5.1 Introduction

5.2 Market Dynamics

5.3 COVID-19 Pandemic-Driven Market Dynamics and Factor Analysis

6.1 Introduction

6.2 Value Chain Analysis

6.3 Porters Five Forces Analysis

6.4 Pricing Analysis

And more

9 Plaque Psoriasis Treatment Market, By Region

10.1 Overview

10.2 Market Evaluation Framework

10.3 Estimated Market Share Range of Key Players

11.1 Overview

11.2 Competitive Leadership Mapping

In4Research narrows down the available data using primary sources to validate the data and use it in compiling a full-fledged market research study. The report contains a quantitative and qualitative estimation of market elements that interests the client. The Global Plaque Psoriasis Treatment Market is mainly bifurcated into sub-segments which can provide classified data regarding the latest trends in the market.

Important Questions Answered by Global Plaque Psoriasis Treatment Market Report

Buy Full Research Report at https://www.in4research.com/buy-now/60819

FOR ALL YOUR RESEARCH NEEDS, REACH OUT TO US AT:

Contact Name: Rohan

Email: [emailprotected]

Phone: +1 (407) 768-2028

Browse More Articles

Civil Engineering Market Overview by Industry Dynamics, Regional Analysis and Forecast 2022 to 2027

Enterprise SaaS Market 2022-2027 Revenue Analysis, Growth rate, Recent Development and Top Players

COVID19 Impact on Freeze-Dried Food Market 2022 Industry Insight and Growth Strategy by Business Players

Chloroacetic Acid Market 2022-2027 Revenue Analysis, Growth rate, Recent Development and Top Players

More:
Plaque Psoriasis Treatment Market 2022 Booming Across the Globe by Share, Growth Size, Key Segments and Forecast to 2027 Construction News Portal -...

PARIS--(BUSINESS WIRE)--CTMA, a clinical research service company that is working to change the way patients are detected for clinical trials, announced that it is expanding its CT-SCOUT technology offering into a second therapeutic area rheumatology. CT-SCOUT, the companys multi-device platform that allows health care professionals (HCP) to identify trial candidates, will now be available for sites, sponsors and contract research organizations (CROs) in three rheumatological indications: Rheumatoid Arthritis, Ankylosing Spondylarthritis and Psoriatic Rheumatism.

Pierre Pellier, Chief Executive Officer of CTMA, said: We are thrilled to expand our platform by adding a new therapeutic area. This enables us to support a larger pool of patients, studies, sites and sponsors. Rheumatoid Arthritis, Ankylosing Spondylarthritis and Psoriatic Rheumatism, are chronic, debilitating diseases that affect a large population of patients for whom clinical trials may represent an important therapeutic alternative solution.

Building on its successful experience in inflammatory bowel disease (IBD), CTMA plans to continue expanding its offering to include additional therapeutic areas in order to accelerate clinical research. Currently, a majority of clinical trials are delayed and up to 10% of trials are never completed. CTMAs technology allows healthcare providers to use an app in real-time alongside a patient, to efficiently identify trials running at the site that will match the patients profile.

Patients suffering from Rheumatoid Arthritis, Ankylosing Spondylarthritis and Psoriatic Rheumatism are still looking for new therapies as there is a large unmet medical need. Ultimately, the goal of CTMAs app-based technology is to help bring innovative therapies to patients faster.

Dr. Emmanuelle Dernis-Labous, a rheumatology expert at the Hospital Center of Le Mans, said: Developing a recruitment algorithm for clinical trials focused on three major rheumatology indications has been a fascinating exercise. This will contribute to making clinical trials more visible and more accessible to patients suffering from these chronic diseases, who are in need of alternative therapeutic options.

About CTMA:

CTMA is a clinical research service company that is working to change the way patients are detected for clinical trials. Based in Paris, the company has developed an innovative solution to address the critical patient detection problem that affects most clinical trials. In 2014, CTMA launched its innovative, patented methodology and application, to increase recruitment in clinical studies. Since then, CTMA has successfully worked with the larger sponsors in inflammatory bowel disease (IBD) ulcerative colitis (UC) and Crohns disease (CD), where it demonstrated that sites equipped with its solution can recruit by up to four times more than non-equipped sites1.

More than 250 investigational sites have benefited from this unique solution so far. For more information, please visit: http://www.ctma.fr.

_________________1Ref: Bouhnik Y, et al. Gastroenterology 2020- https://www.gastrojournal.org/article/S0016-5085(20)30371-1/pdf

See the rest here:
CTMA Expands Its Digital Clinical Trial Solution to a Second Therapeutic Area Rheumatology - Business Wire

Psoriasis is a chronic immune mediated inflammatory disorder that affects approximately 2% of the world population or 140 million people worldwide. In the U.S, approximately 7.4 million adults have psoriasis. This chronic disease is known for its effects on the skin, which occurs when the immune system mistakenly triggers skin cells to overgrow. As a result, the life cycle of cells is sped up and an excess of them can form inflamed patches of skin that may occur anywhere on the body, especially on the elbow, knees, lower back and scalp. Often times, psoriasis has a genetic component, and is known to run in families.

Psoriasis may be associated with diseases of other organs. In fact, according to the Centers for Disease Control and Prevention (CDC), about 10% - 20% of people with psoriasis also suffer from psoriatic arthritis, which causes joint pain and stiffness, and joint destruction (in severe cases). Additionally, research suggests that people living with psoriasis may also have an increased risk for heart disease, stroke, depression and other immune diseases.

Psoriasis can occur in children or adults, however, peak onset of psoriasis often occurs between the ages of 16 to 22 years, or between the ages of 57 and 60 years. The way symptoms appear and their seriousness may vary greatly depending on the type, form and severity of disease.

Psoriasis generally occurs as redness on the skin, raised areas (called plaques or lesions), and silvery white patches (called scales). Other forms of psoriasis can cause additional types of skin conditions. These may include small red spot-like lesions that show up after a bacterial infection (such as strep throat), pus-filled bumps, or intensely sore red patches in body folds (i.e., arm pits, groin, under the breast).

Most often, in psoriasis, the affected skin is found on elbows, knees, lower back, and scalp, though patches can appear just about anywhere. Other places on the body can include face, genitals, fingernails, palms of the hands, and soles of the feet.

Its important to tell your doctor about any skin problems you may be having.While not all skin irregularities are psoriasis, its important to show them to your doctor for an accurate diagnosis, as skin problems can be signs of other illnesses.

There are many different treatment options. Typical therapies include topical treatments (medicine applied to the skin), phototherapy (treatment with ultraviolet light therapy), treatment taken by mouth or injection (conventional therapy), and treatments called biologic (injections or infusions) which target specific immune-system proteins known to play a role in psoriasis inflammation.

With psoriasis, response to therapy may vary by person. Some people will try several approaches until finding one that works well; others will try more than one therapy at a time. Diagnosis, understanding patients needs, appropriate treatment, and check-ins to see if the management plan should continue or be modified are key toward reaching the goals agreed upon by people with psoriasis and their health care teams.

Not everybody understands psoriasis. Some people see skin lesions and fear they will get the disease from being near a person with psoriasis or by touching their skin. People with psoriasis are sometimes asked to leave public places like gyms or pools. This may cause undue stress to someone living with psoriasis, and is completely based on false notions.

Psoriasis is not something you can catch, or that others can catch from you. It is not contagious. Because symptoms on the skin are often visible, coping with other peoples reactions to lesions or plaque can be part of managing psoriasis.Today people living with the disease and their advocates are working to highlight the facts about psoriasis and change the biases based on unfounded fears.

Lotus Mallbris, MD, PhD, was a Senior Medical Director and the global medical lead across several investigational dermatology programs at Pfizer.

Mandeep Kaur, MD, MS was the Therapeutic Team Lead in Dermatology during her employment at Pfizer.

See the article here:
Living with Psoriasis: Beyond Just Skin | Pfizer

Psoriasis is a skin condition that creates red patches of skin with white, flaky scales. It most commonly occurs on the elbows, knees and trunk, but can appear anywhere on the body. The first episode usually strikes between the ages of 15 and 35. It is a chronic condition that will then cycle through flare-ups and remissions throughout the rest of the patient's life. Psoriasis affects as many as 7.5 million people in the United States. About 20,000 children under age 10 have been diagnosed with psoriasis.

In normal skin, skin cells live for about 28 days and then are shed from the outermost layer of the skin. With psoriasis, the immune system sends a faulty signal which speeds up the growth cycle of skin cells. Skin cells mature in a matter of 3 to 6 days. The pace is so rapid that the body is unable to shed the dead cells, and patches of raised red skin covered by scaly, white flakes form on the skin.

Psoriasis is a genetic disease (it runs in families), but is not contagious. There is no known cure or method of prevention. Treatment aims to minimize the symptoms and speed healing.

There are five distinct types of psoriasis:

People who have psoriasis are at greater risk for contracting other health problems, such as heart disease, inflammatory bowel disease and diabetes. It has also been linked to a higher incidence of cardiovascular disease, hypertension, cancer, depression, obesity and other immune-related conditions.

Psoriasis triggers are specific to each person. Some common triggers include stress, injury to the skin, medication allergies, diet and weather.

Psoriasis is classified as Mild to Moderate when it covers 3% to 10% of the body and Moderate to Severe when it covers more than 10% of the body. The severity of the disease impacts the choice of treatments.

Mild to moderate psoriasis can generally be treated at home using a combination of three key strategies: over-the-counter medications, prescription topical treatments and light therapy/phototherapy.

The U.S. Food and Drug Administration has approved of two active ingredients for the treatment of psoriasis: salicylic acid, which works by causing the outer layer to shed, and coal tar, which slows the rapid growth of cells. Other over-the-counter treatments include:

Prescription topicals focus on slowing down the growth of skin cells and reducing any inflammation. They include:

Controlled exposure of skin to ultraviolet light has been a successful treatment for some forms of psoriasis. Three primary light sources are used:

Treatments for moderate to severe psoriasis include prescription medications, biologics and light therapy/phototherapy.

Oral medications. This includes acitretin, cyclosporine and methotrexate. Your doctor will recommend the best oral medication based on the location, type and severity of your condition.

Biologics. A new classification of injectable drugs, biologics are designed to suppress the immune system. These tend to be very expensive and have many side effects, so they are generally reserved for the most severe cases.

Light Therapy/Phototherapy. Controlled exposure of skin to ultraviolet light has been a successful treatment for some forms of psoriasis. Two primary light sources are used:

Here is the original post:
Psoriasis - Melbourne, FL Dermatologist

What is psoriasis?

Psoriasis is a chronic skin condition that occurs when the skin cells are replaced too rapidly. Normally, it takes about a month for new skin cells to migrate from the lower layers of skin to the skins surface, and as new cells reach the surface, old, worn-out cells are shed, creating a continual replacement process that supports healthy skin. In psoriasis, this replacement cycle process is sped up, with new skin cells migrating to the surface in just a few days instead of a month. As the skin cells near the surface, they create a backlog of unshed surface cells, forming large patches of thick, scaly skin called plaques. Although the specific underlying cause of psoriasis isnt known, research indicates the condition is related to an immune disorder that interferes with the normal skin replenishment cycle. Psoriasis plaques can be unsightly and embarrassing, but the disease is not contagious, which means it cannot be spread from one person to another.

Psoriasis is usually identifiable by the recurrent plaques of scaly, itchy skin that develop. These plaques can appear red or pink with a silvery or whitish sheen. Plaques tend to occur most commonly around the elbows and knees, but they can occur elsewhere as well. Other symptoms include:

Some people develop psoriatic arthritis, a painful condition that causes aching in the joints and joint stiffness. The best way to know for sure if you have psoriasis is to have an evaluation by a skilled dermatologist who can diagnose the condition with a physical exam, sometimes accompanied by a biopsy to rule out other conditions.

To date, there is no cure for psoriasis, but there are several treatments that can help reduce flare-ups and help keep symptoms under control. Prescription-strength topical medications and oral medications are effective in helping many patients manage their symptoms, and some patients benefit from phototherapy that uses precise measured doses of light to reduce scaly, itchy plaques.

Continued here:
Psoriasis Specialist - Melbourne, FL & Titusville, FL ...

Psoriasis is a skin condition that creates red patches of skin with white, flaky scales. It most commonly occurs on the elbows, knees and trunk, but can appear anywhere on the body. The first episode usually strikes between the ages of 15 and 35. It is a chronic condition that will then cycle through flare-ups and remissions throughout the rest of the patient's life. Psoriasis affects as many as 7.5 million people in the United States. About 20,000 children under age 10 have been diagnosed with psoriasis.

In normal skin, skin cells live for about 28 days and then are shed from the outermost layer of the skin. With psoriasis, the immune system sends a faulty signal which speeds up the growth cycle of skin cells. Skin cells mature in a matter of 3 to 6 days. The pace is so rapid that the body is unable to shed the dead cells, and patches of raised red skin covered by scaly, white flakes form on the skin.

Psoriasis is a genetic disease (it runs in families), but is not contagious. There is no known cure or method of prevention. Treatment aims to minimize the symptoms and speed healing.

There are five distinct types of psoriasis:

People who have psoriasis are at greater risk for contracting other health problems, such as heart disease, inflammatory bowel disease and diabetes. It has also been linked to a higher incidence of cardiovascular disease, hypertension, cancer, depression, obesity and other immune-related conditions.

Psoriasis triggers are specific to each person. Some common triggers include stress, injury to the skin, medication allergies, diet and weather.

Psoriasis is classified as Mild to Moderate when it covers 3% to 10% of the body and Moderate to Severe when it covers more than 10% of the body. The severity of the disease impacts the choice of treatments.

Mild to moderate psoriasis can generally be treated at home using a combination of twokey strategies: over-the-counter medications andprescription topical treatments.

The U.S. Food and Drug Administration has approved of two active ingredients for the treatment of psoriasis: salicylic acid, which works by causing the outer layer to shed, and coal tar, which slows the rapid growth of cells. Other over-the-counter treatments include:

Prescription topicals focus on slowing down the growth of skin cells and reducing any inflammation. They include:

Treatments for moderate to severe psoriasis include prescription medications and biologics.

Oral medications. This includes acitretin, cyclosporine and methotrexate. Your doctor will recommend the best oral medication based on the location, type and severity of your condition.

Biologics. A new classification of injectable drugs, biologics are designed to suppress the immune system. These tend to be very expensive and have many side effects, so they are generally reserved for the most severe cases.

More here:
Psoriasis - Kissimmee & Windermere, FL Dermatologists ...

Transcript:

Lakshi Aldredge, MSN, ANP-BC, DCNP: Weve covered a lot. We talked about topical treatments, we touched on phototherapy, we talked about the oral treatments, and then the different class of biologic agents, including the TNF [tumor necrosis factor]alpha inhibitors, IL-17s and the IL-23s. Thats whats exciting: theres even more research thats happening in the field of psoriasis, and there are new agents coming into the field. Can you talk a little about whats coming down the pipeline?

Matthew Brunner, MHS, PA-C, DFAAPA: Im really excited. First, we have just seen such an explosion of immunology, knowledge, education, and therapeutics in the last 20 years. And that knowledge and advancements continuing. There are new classes of immunologic agents called tyrosine kinase inhibitors [TKIs], and theyre hopefully going to be entering the fray very soon. Theyre going to offer another modality and an oral agent that patients will be able to take, hopefully with more convenient dosing options and good safety. Well see all that come to fruition.

Then theres this topical therapeutic aryl hydrocarbon receptor modulating agents that are being studied in both psoriasis and atopic dermatitis. And we may see those in both topical and systemic iterations down the road. The future has never been brighter to be a psoriasis patient. I tell my patients all the time, its never great to have psoriasis, but youve never lived at a better time to have psoriasis. Every time I see them back in a future visit, the same holds true because new agents are comingnew targets, to help them manage their conditionare being brought to market. Its really exciting. What do you think about the future?

Lakshi Aldredge, MSN, ANP-BC, DCNP: You said it very well. Its such a great time to be in the field of psoriasis management because there continues to be such activity and research. We have very passionate researchers who are really looking to find a cure. In the meantime, finding all these targets that help improve the skin, help improve the joints. There new agents coming out, but its also important to understand that, for example, with the IL-23s, there are new indications being studied. Right now, many of the IL-23s are indicated for moderate to severe psoriasis in adult patients. Were going to see clinical trials that are being completed currently in adolescents and in pediatrics. Thats something that we can look forward to. Also, we can look forward to data that are going to be coming shortly about psoriatic arthritis and the use of IL-23 inhibitors in psoriatic arthritis disease. Thats going to be very promising as well.

You said it perfectly: the future has never looked brighter for our patients with psoriasis. As we move toward the goal of clear or near-clear skin and also looking at them holistically, helping prevent the development or worsening of those other comorbiditiessuch as metabolic syndrome, psychosocial disease, and cardiovascular riskall these treatment modalities can help us help our patients with psoriasis to live long and healthy, happy, successful lives. Thats our role as NPs [nurse practitioners] and PAs [physician assistants] in dermatology. Its a very exciting time.

Matthew Brunner, MHS, PA-C, DFAAPA: Thank you for joining me today. This has been really a fun conversation. Hopefully its been educational for those of you watching. Thank you for watching HCPLive Peers & Perspectives. If you enjoyed the content, please subscribe to our e-newsletters to receive upcoming Peers & Perspectives and other great content right in your in-box.

Transcript edited for clarity.

Go here to see the original:
Anticipated Developments in the Field of Plaque Psoriasis - MD Magazine

Psoriasis, a common autoimmune disorder that impacts over a million South Africans,1 is often misunderstood to be a simple skin disorder. This couldnt be further from the truthpsoriasis is a serious chronic disorder that negatively impacts the overall health of a person, and can present with serious co-morbidities such as heart, lung and kidney problems.2

Unlike other chronic diseases, psoriasis is visible to other people. This makes the disease even more complicated and debilitating, as many patients also suffer with mental health challenges such as anxiety, depression, poor self-esteem and relationship challenges. A recent study found that one third of adults living with psoriasis said that the disease interferes with their love life.3

Sharon* was just seven years old when she had a severe case of chicken pox that left 90% of her body inflamed with painful burning scales. After a visit to a dermatologist, Sharon was diagnosed with psoriasis and has lived with this debilitating skin disease for over thirty years. This is Sharons story.

When my symptoms of psoriasis started, there werent many treatment options available and over the years, I tried a myriad of creams and UVA light therapies. Unfortunately, nothing helped me achieve clear skin, said Sharon. My life was filled with burning, itchy and embarrassing skin, at times I felt trapped alone at home. Those rare times that I did venture out, I hid my skin under layers of clothes.

My psychological pain and anguish were worse than the pain of my skin, added Sharon. At that time, my doctors didnt seem to consider my emotional suffering and the impact psoriasis had on my whole life. It all became so unbearable that I went to the darkest places of my mind and considered ending my life.

namtipStudio/shutterstock

Shortly after I considered suicide, I had a heart-to-heart with my doctor, who prescribed a biologic treatment, said Sharon. Initially, I didnt have much hope, until I saw the difference it made to my skin. For the first time in years, I felt comfortable to wear sleeveless clothing and go out without covering up. I was overcome by joy!

In addition to the right medication, lifestyle changes can also make a difference.

Its important to get the right treatment for your condition. Psoriasis patients are urged to motivate and pressurise their medical aid to cover the cost of treatment as it is a chronic and debilitating disease. In addition, it is your constitutional right to access healthcare.

Psoriasis impacts people in different ways, and requires individual treatment, says Dr Noufal Raboobee, a dermatologist based in Durban South Africa. While each patient requires a unique treatment plan, whats critical is that they find the right treatment plan to achieve clear skin, and do so before the disease escalates and causes additional health co-morbidities. Everyone deserves to live a fulfilled life without pain and shame.

If you, or a loved one is experiencing dry, painful, scaly skin that just wont heal, or any other symptoms of psoriasis, talk to a dermatologist. You can also learn more about psoriasis by visiting the #MoreThanSkinDeep page on Facebook. Remember, psoriasis can be treated and clear skin is achievable and its your right to get the treatment you need to live a healthy, fulfilled life.

*Name of patient has been changed for privacy reasons.

Read more:
Living With Psoriasis. A Sufferer Shares Her Thoughts - Longevity LIVE - Longevity LIVE

Patients with psoriasis exhibited superior efficacy outcomes when treated with ultraviolet (UV)-based phototherapy plus other adjuvant therapies vs UV monotherapy, with similar safety profiles shown for both approaches.

The efficacy of ultraviolet (UV)-based phototherapy for psoriasis may be improved when combined with other adjuvant therapies, according to study findings published last week in Annals of Medicine.

Beyond the use of systemic therapies such as oral retinoids or biologics, UV-based phototherapy with UVB or psoralen UVA (PUVA) has been shown to be a well-established and generally effective therapeutic option for the treatment of psoriasis. Moreover, researchers said that although systemic and biological treatments are strongly recommended for severe and diffuse skin diseases, these medications can cause systemic adverse effects and immunosuppression.

These UV-based phototherapies, along with their combination with other treatments, are thought to be effective treatments for many patients with psoriasis, leading to an urgent demand for comparative studies of efficacy referring to clinical decision-making, they noted.

Seeking to compare the clinical efficacy and safety profile of different UV-based phototherapies in the treatment of psoriasis, the investigators conducted a meta-analysis of randomized controlled trials registered in the PubMed, Cochrane Library, Scopus, and Embase databases.

UV-based therapies were assessed as a monotherapy or in combination with various drugs and remedies, including systematic treatments, skin lubricants, vitamins, and vitamin derivatives in the treatment of moderate to severe psoriasis. Five phototherapy strategies were identified and analyzed:

The primary outcome for assessing effectiveness and safety was Psoriasis Area and Severity Index (PASI) 75 response (75% or more reduction in PASI score from baseline) and withdrawal due to adverse events, in which effects were ranked and calculated by surface under the cumulative ranking analysis (SUCRA).

In the meta-analysis, 32 studies involving 2120 patients with psoriasis (mean age, 41.5 years; 61.6% male) were included. Compared with monotherapy of PUVA and UVB, PASI 75 response was significantly higher in those treated with cPUVA (risk ratio [RR], 1.39; 95% CI, 1.00-1.94) and cUVB (RR, 1.27; 95% CI, 1.03-1.57), respectively. Moreover, PUVA combined with vitamin D and its derivatives ranked highest concerning clinical effect and safety (clusterank value = 7393.2).

Regarding safety, no significant difference was reported for withdrawal due to adverse events or incidence of erythema. The relatively safest strategy was cPUVA, particularly PUVA combined with calcium/vitamin D derivatives (RR, 0.98; 95% CI, 0.30-3.17; SUCRA = 80.8%).

cPUVA and cUVB, especially combined with calcium/vitamin D derivatives, are both safe and effective treatments for psoriasis and have the potential for the first choice in the treatment of moderate to severe psoriasis, concluded the researchers. However, more high-quality trials are necessary for confirming our findings.

Reference

Li Y, Cao Z, Guo J, et al. Assessment of efficacy and safety of UV-based therapy for psoriasis: a network meta-analysis of randomized controlled trials. Ann Med. Published online January 6, 2022. doi:10.1080/07853890.2021.2022187

Continued here:
Adjuvant Ultraviolet-Based Therapy More Effective vs Monotherapy in Psoriasis - AJMC.com Managed Markets Network